Salix Pharmaceuticals, Inc, Internet Privacy Statement

Salix Pharmaceuticals, Inc, Internet Privacy Statement

Salix Pharmaceuticals, Inc ("Salix"), respects the privacy of visitors to our site (the "Site") and is committed to maintaining your privacy when you visit. Salix will only collect your personally identifiable information when you voluntarily provide it to us. From time to time, we may refer to this information to better understand your needs and how we can improve our services. We may use this information to contact you; however, we will not sell the personally identifiable information you provide to us at this website to any third parties for their own use.

As many other companies do, Salix measures the performance of its Site in order to improve and customize it in favor of our visitors. Salix's website may use a technology called "cookies." Generally, a cookie assigns a unique number to the visitor that has no meaning outside the assigning site. The purpose of this technology and the information it provides is to help us improve our Site. Most Web browsers allow the user to deny or accept the cookie feature. Please note that cookies may be necessary to provide you with certain features available on the Salix Site. In all cases in which cookies are used, neither Salix nor any third party will use the cookie to collect personally identifiable information unless you voluntarily agree to enter the information.

Salix's website may also maintain Web server logs that can automatically identify your computer by its IP address and collect that information. An IP address is a number that is automatically assigned to your computer by your Internet service provider. Salix's Web server logs may collect statistical data that are generated by your computer when it visits Salix's website, such as the type of Web browser used to access the Site and the pages you visit. No personally identifiable information would be contained in these Web server logs.

Some services on our Site may require registration. When you register, you may need to complete certain fields as well as choose a user name and password. In these situations, if you choose to withhold any personally identifiable information requested by us, it may not be possible for you to gain access to certain parts of the Site and for us to respond to your query. Please see our Terms and Conditions for more information.

The Privacy Policy does not apply to those websites to which the Salix Site may provide links. You should contact those websites directly for information on their privacy policies. Salix reserves its right to amend this policy at any time.

This Site is intended for US residents only.

Created 7/02

Revised 3/10

Indication for RELISTOR

RELISTOR® is indicated for the treatment of opioid-induced constipation (OIC) in patients with advanced illness who are receiving palliative care, when response to laxative therapy has not been sufficient. Use of RELISTOR beyond four months has not been studied.

Important Safety Information about RELISTOR

Do not take RELISTOR® (methylnaltrexone bromide) Subcutaneous Injection if you have or may have a blockage in your intestines called a mechanical bowel obstruction. Symptoms of this blockage are vomiting, stomach pain, and swelling of your abdomen. Talk to your healthcare provider if you have any of these symptoms before taking RELISTOR.

Cases of holes or openings in your gastrointestinal (GI) tract have been reported in adult patients with opioid-induced constipation and advanced illness with certain conditions (i.e., cancer, peptic ulcer, Ogilvie's syndrome). These holes or openings have involved varying regions of the GI tract (e.g., stomach or intestines). Use RELISTOR with caution if you have a known or suspected wound or injury to the GI tract. If you get abdominal pain that is severe or will not go away, or nausea or vomiting that is new or worse, stop taking RELISTOR and call your healthcare provider.

If you get diarrhea that is severe or does not stop while taking RELISTOR, stop taking RELISTOR and call your healthcare provider.

Use of RELISTOR beyond four months has not been studied.

Safety and efficacy of RELISTOR have not been established in children.

The most common side effects of RELISTOR in clinical studies include: abdominal (stomach) pain, gas, nausea, dizziness, diarrhea, and sweating.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch/ or call 1-800-FDA-1088.

For product information, adverse event reports, and product complaint reports, please contact:

Salix Product Information Call Center
Phone: 1-800-508-0024
Fax: 1-510-595-8183
Email: salix@medcomsol.com

Please see complete Prescribing Information for RELISTOR.